ZachXBT Alleges Insider Control in LAB Token Inquiry
ZachXBT alleges insider control as LAB token scrutiny rises amid an investigation into AI Terminal's $6 billion FDV p...
Planning retirement at 40 requires careful consideration of various factors. Learn key elements to secure your financial future.
18,889 articlesZachXBT alleges insider control as LAB token scrutiny rises amid an investigation into AI Terminal's $6 billion FDV p...
Wolverine Worldwide's Q1 2026 earnings call offers a clear view of the company's momentum, margins, and strategic bet...
As Mink (INKT) closes 2025, investors want clarity on growth, margins, and cash generation. This analysis breaks down...
Rocket Lab stock has hit an all-time high, but savvy investors know a rally is more than a headline. This guide break...
Major appliance brands warn buyers to pace big-ticket purchases as demand cools and prices rise. The article surveys ...
Investors eyeing SPRY's Q1 2026 results should understand how to parse a pharma earnings transcript. This guide break...
A Nvidia-backed AI infrastructure player is quietly reshaping how enterprises train and run AI. This piece breaks dow...
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Hesai's early 2026 earnings signal a turning point for LiDAR tech adoption. This guide breaks down the Q1 results, wh...
Stifel boosted CrowdStrike’s target to $660 ahead of the June earnings release, signaling renewed optimism on growth ...
A timely analysis of pff’s billion preferred stock exposure reveals how call provisions and a bank-heavy portfolio co...
The market presses higher as investors cling to earnings resilience and policy stability, with AI and defense leading...